Touchlight To Disrupt DNA Market With Synthetic Manufacturing
Touchlight Positions Itself To Meet Coming Demand For ‘100s of kilograms of DNA’
Executive Summary
Touchlight has secured £42m ($60m) in funding to support efforts to triple its manufacturing capacity of synthetic DNA based on the company’s proprietary dbDNA platform – an enzyme made minimal linear DNA vector. The completed facility will have the capacity to produce 1kg of GMP DNA per month, enough for one billion COVID-19 vaccine doses.